CL2014003173A1 - Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona - Google Patents

Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona

Info

Publication number
CL2014003173A1
CL2014003173A1 CL2014003173A CL2014003173A CL2014003173A1 CL 2014003173 A1 CL2014003173 A1 CL 2014003173A1 CL 2014003173 A CL2014003173 A CL 2014003173A CL 2014003173 A CL2014003173 A CL 2014003173A CL 2014003173 A1 CL2014003173 A1 CL 2014003173A1
Authority
CL
Chile
Prior art keywords
modulators
glucocorticoid receptor
fused azadecalin
heteroaryl ketone
azadecalin glucocorticoid
Prior art date
Application number
CL2014003173A
Other languages
English (en)
Spanish (es)
Inventor
Nicholas Ray
Hazel Hunt
Tony Johnson
Lain Walters
Original Assignee
Corcept Therapeuticas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeuticas Inc filed Critical Corcept Therapeuticas Inc
Publication of CL2014003173A1 publication Critical patent/CL2014003173A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Electroluminescent Light Sources (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2014003173A 2012-05-25 2014-11-21 Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona CL2014003173A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651669P 2012-05-25 2012-05-25
US201261691083P 2012-08-20 2012-08-20
US201261715907P 2012-10-19 2012-10-19
US201361759520P 2013-02-01 2013-02-01
US201361781629P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
CL2014003173A1 true CL2014003173A1 (es) 2015-02-27

Family

ID=49624542

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003173A CL2014003173A1 (es) 2012-05-25 2014-11-21 Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona

Country Status (23)

Country Link
EP (5) EP3590517B1 (US07476746-20090113-C00133.png)
JP (1) JP6172871B2 (US07476746-20090113-C00133.png)
KR (1) KR102062640B1 (US07476746-20090113-C00133.png)
CN (1) CN104619328B (US07476746-20090113-C00133.png)
AU (1) AU2013266110C1 (US07476746-20090113-C00133.png)
BR (1) BR112014028857B1 (US07476746-20090113-C00133.png)
CA (1) CA2872260C (US07476746-20090113-C00133.png)
CL (1) CL2014003173A1 (US07476746-20090113-C00133.png)
DK (4) DK3851107T3 (US07476746-20090113-C00133.png)
ES (4) ES2930298T3 (US07476746-20090113-C00133.png)
HK (2) HK1208818A1 (US07476746-20090113-C00133.png)
IL (1) IL235868A (US07476746-20090113-C00133.png)
MX (1) MX365423B (US07476746-20090113-C00133.png)
MY (1) MY172739A (US07476746-20090113-C00133.png)
NZ (1) NZ701469A (US07476746-20090113-C00133.png)
PE (1) PE20150352A1 (US07476746-20090113-C00133.png)
PH (1) PH12014502584A1 (US07476746-20090113-C00133.png)
PL (4) PL2854814T3 (US07476746-20090113-C00133.png)
PT (4) PT3590517T (US07476746-20090113-C00133.png)
RU (1) RU2639867C2 (US07476746-20090113-C00133.png)
SG (1) SG11201407682TA (US07476746-20090113-C00133.png)
WO (1) WO2013177559A2 (US07476746-20090113-C00133.png)
ZA (1) ZA201408182B (US07476746-20090113-C00133.png)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PL3848027T3 (pl) * 2013-11-25 2023-07-24 Corcept Therapeutics Incorporated Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego
EP3265127B1 (en) * 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
ES2906778T3 (es) 2015-03-30 2022-04-20 Corcept Therapeutics Inc Uso de antagonistas del receptor de glucocorticoides en combinación con glucocorticoides para tratar la insuficiencia suprarrenal
MX2017014857A (es) 2015-05-18 2018-08-15 Corcept Therapeutics Inc Metodos para diagnosticar y evaluar tratamiento para sindrome de cushing.
JP6768789B2 (ja) * 2015-08-13 2020-10-14 コーセプト セラピューティクス, インコーポレイテッド Acth依存性クッシング症候群を鑑別診断する方法
IL297201A (en) * 2016-03-01 2022-12-01 Corcept Therapeutics Inc Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
EP3641780A4 (en) * 2017-06-20 2021-02-24 Corcept Therapeutics, Inc. TREATMENT METHODS OF NEURO-EPITHELIAL TUMORS USING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
JP7176001B2 (ja) * 2018-04-23 2022-11-21 コーセプト セラピューティクス, インコーポレイテッド 位置選択的n-アルキルトリアゾールを調製する方法
UA125365C2 (uk) 2018-11-09 2022-02-23 Корсепт Терапьютікс Інкорпорейтед Спосіб зменшення розміру видимої пухлини гіпофіза
WO2020132023A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CA3122581A1 (en) 2018-12-20 2020-06-25 Corcept Therapeutics Incorporated Methods for imaging and treatment of somatostatin-receptor positive tumors
BR112021015129A2 (pt) * 2019-02-22 2021-09-28 Corcept Therapeutics Incorporated Método para tratar um paciente que sofre de hipercortisolemia e um sintoma ou comorbidade da mesma
AU2020367769B2 (en) * 2019-10-16 2023-10-12 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
EP4072556A4 (en) 2019-12-11 2024-01-03 Corcept Therapeutics Incorporated METHOD FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN WITH MIRICORILANT
EP4076470A4 (en) 2019-12-21 2023-11-22 Corcept Therapeutics Incorporated DIFFERENTIAL TREATMENT AND DIAGNOSIS BETWEEN ACTH-DEPENDENT CUSHING SYNDROME AND ACTH-INDEPENDENT CUSHING SYNDROME
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
TW202246260A (zh) * 2021-02-03 2022-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合的氮雜三環類衍生物、其製備方法及其在醫藥上的應用
US20240131020A1 (en) * 2022-10-06 2024-04-25 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
DK1735308T3 (da) * 2004-03-09 2009-01-19 Corcept Therapeutics Inc Kondenserede azadecalinringe som glucocorticoidreceptormodulatorer
US7640389B2 (en) * 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
US8598154B2 (en) * 2010-08-27 2013-12-03 Corcept Therapeutics, Inc. Pyridyl-amine fused azadecalin modulators

Also Published As

Publication number Publication date
PH12014502584B1 (en) 2015-01-21
DK3590517T3 (da) 2021-05-03
EP4119561A1 (en) 2023-01-18
BR112014028857A2 (pt) 2017-08-15
EP3590517A1 (en) 2020-01-08
PT3338781T (pt) 2019-11-29
PH12014502584A1 (en) 2015-01-21
RU2639867C2 (ru) 2017-12-25
MY172739A (en) 2019-12-11
HK1208818A1 (en) 2016-03-18
EP3338781A1 (en) 2018-06-27
CA2872260C (en) 2020-12-22
EP2854814A4 (en) 2016-01-27
NZ701469A (en) 2017-06-30
SG11201407682TA (en) 2014-12-30
PL3590517T3 (pl) 2021-09-20
KR20150021955A (ko) 2015-03-03
ES2665338T3 (es) 2018-04-25
EP2854814B1 (en) 2018-01-31
ES2873949T3 (es) 2021-11-04
AU2013266110B2 (en) 2017-04-20
PT2854814T (pt) 2018-03-15
WO2013177559A2 (en) 2013-11-28
PT3851107T (pt) 2022-10-28
PE20150352A1 (es) 2015-03-16
CN104619328B (zh) 2018-10-02
HK1250014B (zh) 2020-06-12
RU2014152625A (ru) 2016-07-20
AU2013266110A1 (en) 2014-11-20
DK2854814T3 (en) 2018-03-12
IL235868A (en) 2017-12-31
IL235868A0 (en) 2015-01-29
AU2013266110C1 (en) 2018-07-12
MX2014014239A (es) 2015-08-05
BR112014028857B1 (pt) 2021-09-28
DK3338781T3 (da) 2019-12-09
CN104619328A (zh) 2015-05-13
PL2854814T3 (pl) 2018-07-31
CA2872260A1 (en) 2013-11-28
EP2854814A2 (en) 2015-04-08
JP2015517580A (ja) 2015-06-22
KR102062640B1 (ko) 2020-01-06
ES2753816T3 (es) 2020-04-14
EP3590517B1 (en) 2021-03-17
PL3851107T3 (pl) 2023-03-06
ZA201408182B (en) 2017-09-27
EP3851107B1 (en) 2022-10-19
DK3851107T3 (da) 2022-11-21
PL3338781T3 (pl) 2020-03-31
EP3851107A1 (en) 2021-07-21
EP3338781B1 (en) 2019-09-11
MX365423B (es) 2019-06-03
WO2013177559A3 (en) 2014-01-16
ES2930298T3 (es) 2022-12-09
JP6172871B2 (ja) 2017-08-02
PT3590517T (pt) 2021-04-07

Similar Documents

Publication Publication Date Title
CL2014003173A1 (es) Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona
ZA201604026B (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HRP20182004T1 (hr) Tetrahidropiridopirazini modulatori gpr6
SMT201700009B (it) Modulatori del recettore x del fegato
SMT201600374B (it) Modulatori del recettore x del fegato
DK2964229T3 (da) Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren
HK1223353A1 (zh) 受體調節劑
CO7190237A2 (es) Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona
ITMI20120786A1 (it) Modulatori del recettore gpr17